SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-020859
Filing Date
2023-05-11
Accepted
2023-05-11 08:10:54
Documents
14
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rapt-20230511.htm   iXBRL 8-K 55133
2 EX-99.1 rapt-ex99_1.htm EX-99 196648
3 GRAPHIC img152904466_0.jpg GRAPHIC 3854
  Complete submission text file 0000950170-23-020859.txt   384237

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rapt-20230511.xsd EX-101.SCH 2457
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rapt-20230511_lab.xml EX-101.LAB 13350
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rapt-20230511_pre.xml EX-101.PRE 9832
8 EXTRACTED XBRL INSTANCE DOCUMENT rapt-20230511_htm.xml XML 4713
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

IRS No.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38997 | Film No.: 23908956
SIC: 2834 Pharmaceutical Preparations